Akari Therapeutics PLC Share Price Today: Live Updates & Key Insights

Akari Therapeutics PLC share price today is $0.1449, up -10.65%. The stock opened at $0.1415 against the previous close of $0.1456, with an intraday high of $0.1499 and low of $0.1308.

Akari Therapeutics PLC Share Price Chart

Akari Therapeutics PLC

us-stock
To Invest in {{usstockname}}
us-stock

Akari Therapeutics PLC Share Price Performance

$0.1449 -0.1065(-10.65%) AKTX at 23 Mar 2026 11:57 AM Biotechnology
Lowest Today 0.1308
Highest Today 0.1499
Today’s Open 0.1415
Prev. Close 0.1456
52 Week High 1.58
52 Week Low 0.13
Day’s Range: Low 0.1308 High 0.1499
52-Week Range: Low 0.13 High 1.58
1 day return -
1 Week return -35.89
1 month return -49.63
3 month return -49.23
6 month return -83.74
1 year return -88.52
3 year return -97.24
5 year return -99.77
10 year return -

Akari Therapeutics PLC Institutional Holdings

Armistice Capital, LLC 5.95

Cresset Asset Management, LLC 1.80

Palo Alto Investors, LLC 0.32

HighTower Advisors, LLC 0.17

Jane Street Group LLC 0.16

SmartHarvest Portfolios, LLC 0.15

CWA Asset Management Group, LLC 0.12

HPM Partners LLC 0.05

Virtu Financial LLC 0.05

Skyview Financial Group LLC 0.04

Independent Advisor Alliance 0.04

LUX IM Global Medtech HX 0.02

Goss Wealth Management LLC 0.01

Accent Capital Management LLC 0.01

RiverNorth Marketplace Lending Corp 0.00

RiverNorth Opportunities 0.00

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

Truvestments Capital LLC 0.00

UBS Group AG 0.00

Cornerstone Planning Group LLC 0.00

EverSource Wealth Advisors, LLC 0.00

Morgan Stanley - Brokerage Accounts 0.00

Akari Therapeutics PLC Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Akari Therapeutics PLC Fundamentals

Market Cap 16.96 M

PB Ratio 0.2623

PE Ratio 0.0

Enterprise Value 5.58 M

Total Assets 50.56 M

Volume 345857

Akari Therapeutics PLC Company Financials

Annual Revenue FY23:null 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-4000 -0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-10008000 -10.0M, FY22:-6972252 -7.0M, FY21:-17606856 -17.6M, FY20:-17597000 -17.6M, FY19:-21764000 -21.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:25998 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:-1000 -0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-6361564 -6.4M, Q2/2025:-1895000 -1.9M, Q1/2025:-3705000 -3.7M, Q3/2024:-2895000 -2.9M, Q2/2024:-7558000 -7.6M

About Akari Therapeutics PLC & investment objective

Company Information Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Mr. Abizer Gaslightwala

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Akari Therapeutics PLC FAQs

What is the share price of Akari Therapeutics PLC today?

The current share price of Akari Therapeutics PLC is $0.1449.

Can I buy Akari Therapeutics PLC shares in India?

Yes, Indian investors can buy Akari Therapeutics PLC shares by opening an international trading and demat account with Motilal Oswal.

How to buy Akari Therapeutics PLC shares in India?

You can easily invest in Akari Therapeutics PLC shares from India by:

Can I buy fractional shares of Akari Therapeutics PLC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Akari Therapeutics PLC?

Akari Therapeutics PLC has a market cap of $16.96 M.

In which sector does Akari Therapeutics PLC belong?

Akari Therapeutics PLC operates in the Biotechnology sector.

What documents are required to invest in Akari Therapeutics PLC stocks?

To invest, you typically need:

What is the PE and PB ratio of Akari Therapeutics PLC?

The PE ratio of Akari Therapeutics PLC is N/A and the PB ratio is 0.26.